A Phase 2 interventional study of Elsubrutinib and Upadacitinib in Rheumatoid Arthritis (RA), sponsored by AbbVie. Terminated at 30 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-16.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing upadacitinib in Arthritis, Rheumatoid — 3 open to participants now, 3 under way, none of them phase 3. upadacitinib · Arthritis, Rheumatoid.
Among the 19 studies testing upadacitinib in Arthritis, Rheumatoid, this one is the 16th largest by enrollment, is the only one that started in 2019, is one of 7 in phase 2, and was the 12th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 19 studies testing upadacitinib in Arthritis, Rheumatoid are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Toulouse · Sites in France
Ages 18–65
AbbVie
Ages 18+
By country, each count listing its studies:
upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 8 · Phase 4 3
First in 2012; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 97 is close to the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 300 across the 19 interventional studies. Of the 14 that completed or were terminated, 11 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 19 have an industry lead sponsor. The 7 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
80 studies in Arthritis, Rheumatoid by AbbVie: 5 open now, 6 under way, 1 of them phase 3. Of 71 finished, 54 (76%) have results posted.
Among the 80 studies in Arthritis, Rheumatoid by AbbVie, this one is the 25th largest by enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2019, is one of 16 in phase 2, and was the 64th registered.
AbbVie’s Arthritis, Rheumatoid studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing upadacitinib in Arthritis, Rheumatoid, from their registry updates:
Among AbbVie’s 80 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
This was a long-term extension (LTE) study to assess the safety, tolerability, and efficacy of ABBV-105 (elsubrutinib [ELS]) and ABBV-599 (ELS 60 mg and upadacitinib [UPA] 15 mg) in participants with rheumatoid arthritis (RA) who completed Study M16-063 (NCT03682705).
This was a Phase 2, double-blind, multicenter, long-term extension (LTE) study to assess the safety, tolerability, and efficacy of 3 doses of ABBV-105 (elsubrutinib [ELS] 5 mg, 20 mg, and 60 mg) and ABBV-599 (ELS 60 mg and upadacitinib [UPA] 15 mg) in adults with active rheumatoid arthritis with inadequate response or intolerance to biologic disease-modifying antirheumatic drugs (bDMARDs). Participants who successfully completed treatment in the feeder Study M16-063, a Phase 2 dose exploratory study, were eligible to participate in this study. Those who met eligibility criteria and entered this study receiving ELS, ABBV-599, or UPA from Study M16-063 continued on their previously assigned treatment through termination of this study. Participants originally randomized to placebo in Study M16-063 rolled over to ABBV-599 in a blinded fashion in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks
Drug: Elsubrutinib · Drug: Upadacitinib
60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks
Drug: Elsubrutinib · Drug: Placebo for upadacitinib
20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks
Drug: Elsubrutinib · Drug: Placebo for upadacitinib
5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks
Drug: Elsubrutinib · Drug: Placebo for upadacitinib
15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks
Drug: Upadacitinib · Drug: Placebo for elsubrutinib
Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763
Drug: Elsubrutinib · Drug: Upadacitinib
Elsubrutinib capsule will be administered orally.
Also known as: ABBV-105
Upadacitinib tablet will be administered orally.
Also known as: ABT-494
Placebo capsule for elsubrutinib will be administered orally.
Upadacitinib placebo tablet will be administered orally.
Number of Participants With Adverse Events (AEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug as either having a reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug.
Time frame: On or after the first dose of study drug in Study M16-763, and up to 30 days after the last dose of study drug in Study M16-763, up to 52 weeks
Change in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) From Baseline of Study M16-063 at Each Study Visit in Study M16-763
The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline indicates improvement in disease activity.
Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Percentage of Participants Achieving Low Disease Activity (LDA) Based on Disease Activity Score 28 C-reactive Protein (DAS28-CRP)
The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Low Disease Activity (LDA) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than or equal to 3.2.
Time frame: Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Percentage of Participants Achieving Clinical Remission (CR) Based on Disease Activity Score 28 C-reactive Protein (DAS28-CRP)
The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Clinical Remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than 2.6.
Time frame: Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Change in Clinical Disease Activity Index (CDAI) From Baseline of Study M16-063
The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. A negative change from Baseline indicates improvement in disease activity.
Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Percentage of Participants Achieving Low Disease Activity (LDA) Based on Clinical Disease Activity Index (CDAI) Criteria
The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Low Disease Activity (LDA) based on CDAI is defined as achieving a total CDAI score of less than or equal to 10.
Time frame: Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Percentage of Participants Achieving Clinical Remission (CR) Based on Clinical Disease Activity Index (CDAI) Criteria
The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Complete Remission (CR) based on CDAI is defined as achieving a total CDAI score of less than or equal to 2.8.
Time frame: Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response
Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 20% response (ACR20) criteria: 1. ≥ 20% improvement in 68-tender joint count from Baseline of Study M16-063 2. ≥ 20% improvement in 66-swollen joint count from Baseline of Study M16-063 and 3. ≥ 20% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063: * Patient's Assessment of Pain (Visual Analog Scale \[VAS\]) * Patient's Global Assessment of Disease Activity (PtGA) * Physician's Global Assessment of Disease Activity (PhGA) * Health Assessment Questionnaire Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP)
Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response
Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 50% response (ACR50) criteria: 1. ≥ 50% improvement in 68-tender joint count from Baseline of Study M16-063 2. ≥ 50% improvement in 66-swollen joint count from Baseline of Study M16-063 and 3. ≥ 50% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063: * Patient's Assessment of Pain (Visual Analog Scale \[VAS\]) * Patient's Global Assessment of Disease Activity (PtGA) * Physician's Global Assessment of Disease Activity (PhGA) * Health Assessment Questionnaire Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP)
Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response
Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 70% response (ACR70) criteria: 1. ≥ 70% improvement in 68-tender joint count from Baseline of Study M16-063 2. ≥ 70% improvement in 66-swollen joint count from Baseline of Study M16-063 and 3. ≥ 70% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063: * Patient's Assessment of Pain (Visual Analog Scale \[VAS\]) * Patient's Global Assessment of Disease Activity (PtGA) * Physician's Global Assessment of Disease Activity (PhGA) * Health Assessment Questionnaire Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP)
Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Change in Swollen Joint Count 66 (SJC66) From Baseline of Study M16-063
Sixty-six joints were assessed for swelling by physical examination. Swelling of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with swelling) to 66 (worst possible score/66 joints with swelling). Negative values indicate improvement from baseline.
Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Change in Tender Joint Count 68 (TJC68) From Baseline of Study M16-063
Sixty-eight joints were assessed for tenderness by physical examination. Pain or tenderness of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with tenderness) to 68 (worst possible score/68 joints with tenderness). Negative values indicate improvement from baseline.
Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Change in Participant's Assessment of Pain (Visual Analog Scale [VAS]) From Baseline of Study M16-063
Participants rated their pain on a visual analogue scale (VAS) of 0 to 100 (mm), with 0 representing no pain and 100 representing the worst possible pain. Negative values indicate improvement from baseline.
Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Change in Patient's Global Assessment of Disease Activity (PtGA) From Baseline of Study M16-063
Participants rated their disease activity for the past 24 hours using a Patient's Global Assessment of Disease Activity Global visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.
Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Change in Physician's Global Assessment of Disease Activity (PhGA) From Baseline of Study M16-063
The physician assessed a participant's disease activity at the time of the visit using a Physician's Global Assessment of Disease visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.
Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Change in Health Assessment Questionnaire Disability Index (HAQ-DI) From Baseline of Study M16-063
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from baseline in the overall score indicates improvement.
Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Change in High-Sensitivity C-Reactive Protein (Hs-CRP) From Baseline of Study M16-063
C-reactive protein is a blood test marker for inflammation in the body, and levels rise in response to inflammation. A negative change from baseline indicates improvement.
Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Change in Morning Stiffness Severity From Baseline of Study M16-063
Morning stiffness severity was assessed by a numeric rating-scale (NRS). Participants rated the severity of morning stiffness during the past week from 0 to 10 with 0 representing "not severe" and 10 "very severe". Negative values indicate improvement from baseline.
Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
| Milestone | ABBV-599 in M16-063/ABBV-599 in M16-763 | ABBV-105 60 mg/UPA Placebo | ABBV-105 20 mg/UPA Placebo | ABBV-105 5 mg/UPA Placebo | UPA 15 mg/ABBV-105 Placebo | Placebo in M16-063/ABBV-599 in M16-763 |
|---|---|---|---|---|---|---|
| Started | 28 | 16 | 12 | 12 | 20 | 9 |
| Completed | 7 | 0 | 2 | 2 | 2 | 1 |
| Not completed | 21 | 16 | 10 | 10 | 18 | 8 |
| Withdrew: Adverse event | 2 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 4 | 2 | 0 | 1 |
| Withdrew: Other, not specified | 19 | 12 | 6 | 8 | 17 | 7 |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug as either having a reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug.
| Participants | ABBV-599 in M16-063/ABBV-599 in M16-763 | ABBV-105 60 mg/UPA Placebo | ABBV-105 20 mg/UPA Placebo | ABBV-105 5 mg/UPA Placebo | UPA 15 mg/ABBV-105 Placebo | Placebo in M16-063/ABBV-599 in M16-763 |
|---|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) | 11 | 10 | 3 | 5 | 7 | 3 |
The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline indicates improvement in disease activity.
| units on a scale | ABBV-599 in M16-063/ABBV-599 in M16-763 | ABBV-105 60 mg/UPA Placebo | ABBV-105 20 mg/UPA Placebo | ABBV-105 5 mg/UPA Placebo | UPA 15 mg/ABBV-105 Placebo | Placebo in M16-063/ABBV-599 in M16-763 |
|---|---|---|---|---|---|---|
| Week 18 | -3.27 (-3.79 to -2.75) | -1.98 (-2.83 to -1.12) | -1.93 (-3.01 to -0.85) | -2.55 (-3.50 to -1.60) | -3.88 (-4.63 to -3.14) | -2.87 (-4.05 to -1.68) |
| Week 24 | -3.43 (-3.90 to -2.95) | -2.62 (-3.56 to -1.68) | -2.02 (-3.18 to -0.86) | -3.20 (-4.10 to -2.30) | -4.02 (-4.62 to -3.43) | -3.61 (-4.94 to -2.28) |
| Week 30 | -3.17 (-3.86 to -2.47) | -2.37 (-3.71 to -1.03) | -1.45 (-2.30 to -0.60) | -3.30 (-4.43 to -2.17) | -3.84 (-4.56 to -3.12) | -4.08 (-4.73 to -3.44) |
| Week 36 | -3.45 (-4.14 to -2.77) | -3.12 (-3.99 to -2.25) | -1.63 (-2.37 to -0.89) | -3.00 (-4.17 to -1.83) | -4.15 (-5.02 to -3.29) | -3.77 (-4.79 to -2.74) |
| Week 48 | -3.55 (-4.32 to -2.78) | -2.77 (-4.92 to -0.62) | -1.68 (-3.10 to -0.27) | -3.16 (-4.49 to -1.84) | -4.38 (-5.67 to -3.09) | -3.86 (-4.88 to -2.85) |
| Week 60 | -4.06 (-4.88 to -3.25) | -3.21 (-22.18 to 15.75) | -2.55 (-6.90 to 1.79) | -3.41 (-4.92 to -1.89) | -4.12 (-5.43 to -2.81) | -3.69 (-5.19 to -2.19) |
The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Low Disease Activity (LDA) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than or equal to 3.2.
| percentage of participants | ABBV-599 in M16-063/ABBV-599 in M16-763 | ABBV-105 60 mg/UPA Placebo | ABBV-105 20 mg/UPA Placebo | ABBV-105 5 mg/UPA Placebo | UPA 15 mg/ABBV-105 Placebo | Placebo in M16-063/ABBV-599 in M16-763 |
|---|---|---|---|---|---|---|
| Week 18 | 78.3 (58.10 to 90.34) | 26.7 (10.90 to 51.95) | 44.4 (18.88 to 73.33) | 20.0 (5.67 to 50.98) | 77.8 (54.79 to 91.00) | 62.5 (30.57 to 86.32) |
| Week 24 | 77.8 (59.24 to 89.39) | 53.8 (29.14 to 76.79) | 44.4 (18.88 to 73.33) | 50.0 (23.66 to 76.34) | 88.2 (65.66 to 96.71) | 85.7 (48.69 to 97.43) |
| Week 30 | 78.3 (58.10 to 90.34) | 76.9 (49.74 to 91.82) | 28.6 (8.22 to 64.11) | 60.0 (31.27 to 83.18) | 87.5 (63.98 to 96.50) | 100 (67.56 to 100.00) |
| Week 36 | 87.5 (69.00 to 95.66) | 87.5 (52.91 to 97.76) | 25.0 (4.56 to 69.94) | 40.0 (16.82 to 68.73) | 91.7 (64.61 to 98.51) | 100 (60.97 to 100.00) |
| Week 48 | 77.8 (54.79 to 91.00) | 66.7 (30.00 to 90.32) | 50.0 (15.00 to 85.00) | 37.5 (13.68 to 69.43) | 87.5 (52.91 to 97.76) | 100 (60.97 to 100.00) |
| Week 60 | 100 (70.09 to 100.00) | 50.0 (9.45 to 90.55) | 100 (34.24 to 100.00) | 60.0 (23.07 to 88.24) | 100 (56.55 to 100.00) | 75.0 (30.06 to 95.44) |
The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Clinical Remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than 2.6.
| percentage of participants | ABBV-599 in M16-063/ABBV-599 in M16-763 | ABBV-105 60 mg/UPA Placebo | ABBV-105 20 mg/UPA Placebo | ABBV-105 5 mg/UPA Placebo | UPA 15 mg/ABBV-105 Placebo | Placebo in M16-063/ABBV-599 in M16-763 |
|---|---|---|---|---|---|---|
| Week 18 | 56.5 (36.81 to 74.37) | 20.0 (7.05 to 45.19) | 11.1 (1.99 to 43.50) | 20.0 (5.67 to 50.98) | 77.8 (54.79 to 91.00) | 50.0 (21.52 to 78.48) |
| Week 24 | 70.4 (51.52 to 84.15) | 53.8 (29.14 to 76.79) | 33.3 (12.06 to 64.58) | 30.0 (10.78 to 60.32) | 70.6 (46.87 to 86.72) | 71.4 (35.89 to 91.78) |
| Week 30 | 65.2 (44.89 to 81.19) | 46.2 (23.21 to 70.86) | 0 (0.00 to 35.43) | 40.0 (16.82 to 68.73) | 87.5 (63.98 to 96.50) | 100 (67.56 to 100.00) |
| Week 36 | 66.7 (46.71 to 82.03) | 62.5 (30.57 to 86.32) | 0 (0.00 to 48.99) | 20.0 (5.67 to 50.98) | 75.0 (46.77 to 91.11) | 66.7 (30.00 to 90.32) |
| Week 48 | 72.2 (49.13 to 87.50) | 66.7 (30.00 to 90.32) | 0 (0.00 to 48.99) | 25.0 (7.15 to 59.07) | 62.5 (30.57 to 86.32) | 83.3 (43.65 to 96.99) |
| Week 60 | 77.8 (45.26 to 93.68) | 50.0 (9.45 to 90.55) | 50.0 (9.45 to 90.55) | 0 (0.00 to 43.45) | 60.0 (23.07 to 88.24) | 75.0 (30.06 to 95.44) |
The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. A negative change from Baseline indicates improvement in disease activity.
| units on a scale | ABBV-599 in M16-063/ABBV-599 in M16-763 | ABBV-105 60 mg/UPA Placebo | ABBV-105 20 mg/UPA Placebo | ABBV-105 5 mg/UPA Placebo | UPA 15 mg/ABBV-105 Placebo | Placebo in M16-063/ABBV-599 in M16-763 |
|---|---|---|---|---|---|---|
| Week 18 | -33.68 (-40.72 to -26.64) | -23.77 (-32.65 to -14.90) | -19.16 (-28.05 to -10.26) | -27.00 (-42.89 to -11.11) | -36.01 (-44.11 to -27.91) | -28.65 (-37.00 to -20.30) |
| Week 24 | -33.47 (-39.66 to -27.27) | -27.20 (-34.18 to -20.22) | -19.84 (-30.65 to -9.03) | -35.59 (-45.25 to -25.93) | -38.27 (-45.66 to -30.88) | -32.93 (-41.70 to -24.15) |
| Week 30 | -32.07 (-40.11 to -24.03) | -22.40 (-34.25 to -10.55) | -16.72 (-22.28 to -11.16) | -35.92 (-46.64 to -25.20) | -36.86 (-46.20 to -27.52) | -34.00 (-42.21 to -25.79) |
| Week 36 | -35.28 (-43.23 to -27.33) | -28.86 (-36.56 to -21.16) | -19.17 (-32.10 to -6.23) | -33.99 (-47.10 to -20.88) | -42.20 (-52.14 to -32.26) | -32.92 (-41.43 to -24.40) |
| Week 48 | -36.26 (-45.44 to -27.08) | -22.58 (-41.15 to -4.02) | -18.87 (-36.40 to -1.33) | -34.77 (-49.11 to -20.44) | -45.69 (-57.45 to -33.93) | -35.72 (-45.75 to -25.69) |
| Week 60 | -37.99 (-49.56 to -26.41) | -29.70 (-216.48 to 157.08) | -24.95 (-78.95 to 29.05) | -37.20 (-56.11 to -18.29) | -43.98 (-58.77 to -29.19) | -34.38 (-46.14 to -22.61) |
The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Low Disease Activity (LDA) based on CDAI is defined as achieving a total CDAI score of less than or equal to 10.
| percentage of participants | ABBV-599 in M16-063/ABBV-599 in M16-763 | ABBV-105 60 mg/UPA Placebo | ABBV-105 20 mg/UPA Placebo | ABBV-105 5 mg/UPA Placebo | UPA 15 mg/ABBV-105 Placebo | Placebo in M16-063/ABBV-599 in M16-763 |
|---|---|---|---|---|---|---|
| Week 18 | 82.6 (62.86 to 93.02) | 40.0 (19.82 to 64.25) | 44.4 (18.88 to 73.33) | 50.0 (21.52 to 78.48) | 77.8 (54.79 to 91.00) | 62.5 (30.57 to 86.32) |
| Week 24 | 88.9 (71.94 to 96.15) | 69.2 (42.37 to 87.32) | 55.6 (26.67 to 81.12) | 80.0 (49.02 to 94.33) | 88.2 (65.66 to 96.71) | 100 (67.56 to 100.00) |
| Week 30 | 78.3 (58.10 to 90.34) | 76.9 (49.74 to 91.82) | 42.9 (15.82 to 74.95) | 80.0 (49.02 to 94.33) | 81.3 (56.99 to 93.41) | 100 (67.56 to 100.00) |
| Week 36 | 86.4 (66.67 to 95.25) | 87.5 (52.91 to 97.76) | 75.0 (30.06 to 95.44) | 70.0 (39.68 to 89.22) | 83.3 (55.20 to 95.30) | 100 (60.97 to 100.00) |
| Week 48 | 77.8 (54.79 to 91.00) | 66.7 (30.00 to 90.32) | 75.0 (30.06 to 95.44) | 62.5 (30.57 to 86.32) | 87.5 (52.91 to 97.76) | 100 (56.55 to 100.00) |
| Week 60 | 100 (70.09 to 100.00) | 50.0 (9.45 to 90.55) | 100 (34.24 to 100.00) | 80.0 (37.55 to 96.38) | 80.0 (37.55 to 96.38) | 75.0 (30.06 to 95.44) |
The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Complete Remission (CR) based on CDAI is defined as achieving a total CDAI score of less than or equal to 2.8.
| percentage of participants | ABBV-599 in M16-063/ABBV-599 in M16-763 | ABBV-105 60 mg/UPA Placebo | ABBV-105 20 mg/UPA Placebo | ABBV-105 5 mg/UPA Placebo | UPA 15 mg/ABBV-105 Placebo | Placebo in M16-063/ABBV-599 in M16-763 |
|---|---|---|---|---|---|---|
| Week 18 | 17.4 (6.98 to 37.14) | 13.3 (3.74 to 37.88) | 11.1 (1.99 to 43.50) | 12.5 (2.24 to 47.09) | 55.6 (33.72 to 75.44) | 25.0 (7.15 to 59.07) |
| Week 24 | 29.6 (15.85 to 48.48) | 23.1 (8.18 to 50.26) | 11.1 (1.99 to 43.50) | 10.0 (1.79 to 40.42) | 58.8 (36.01 to 78.39) | 50.0 (21.52 to 78.48) |
| Week 30 | 26.1 (12.55 to 46.47) | 30.8 (12.68 to 57.63) | 14.3 (2.57 to 51.31) | 30.0 (10.78 to 60.32) | 43.8 (23.10 to 66.82) | 87.5 (52.91 to 97.76) |
| Week 36 | 36.4 (19.73 to 57.05) | 25.0 (7.15 to 59.07) | 25.0 (4.56 to 69.94) | 10.0 (1.79 to 40.42) | 41.7 (19.33 to 68.05) | 50.0 (18.76 to 81.24) |
| Week 48 | 44.4 (24.56 to 66.28) | 33.3 (9.68 to 70.00) | 0 (0.00 to 48.99) | 12.5 (2.24 to 47.09) | 50.0 (21.52 to 78.48) | 100 (56.55 to 100.00) |
| Week 60 | 33.3 (12.06 to 64.58) | 50.0 (9.45 to 90.55) | 50.0 (9.45 to 90.55) | 20.0 (3.62 to 62.45) | 60.0 (23.07 to 88.24) | 50.0 (15.00 to 85.00) |
Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 20% response (ACR20) criteria: 1. ≥ 20% improvement in 68-tender joint count from Baseline of Study M16-063 2. ≥ 20% improvement in 66-swollen joint count from Baseline of Study M16-063 and 3. ≥ 20% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063: * Patient's Assessment of Pain (Visual Analog Scale \[VAS\]) * Patient's Global Assessment of Disease Activity (PtGA) * Physician's Global Assessment of Disease Activity (PhGA) * Health Assessment Questionnaire Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP)
| percentage of participants | ABBV-599 in M16-063/ABBV-599 in M16-763 | ABBV-105 60 mg/UPA Placebo | ABBV-105 20 mg/UPA Placebo | ABBV-105 5 mg/UPA Placebo | UPA 15 mg/ABBV-105 Placebo | Placebo in M16-063/ABBV-599 in M16-763 |
|---|---|---|---|---|---|---|
| Week 18 | 90.9 (72.19 to 97.47) | 80.0 (54.81 to 92.95) | 57.1 (25.05 to 84.18) | 66.7 (35.42 to 87.94) | 88.2 (65.66 to 96.71) | 75.0 (40.93 to 92.85) |
| Week 24 | 96.2 (81.11 to 99.32) | 92.9 (68.53 to 98.73) | 85.7 (48.69 to 97.43) | 77.8 (45.26 to 93.68) | 93.8 (71.67 to 98.89) | 100 (67.56 to 100.00) |
| Week 30 | 86.4 (66.67 to 95.25) | 69.2 (42.37 to 87.32) | 50.0 (18.76 to 81.24) | 80.0 (49.02 to 94.33) | 87.5 (63.98 to 96.50) | 100 (67.56 to 100.00) |
| Week 36 | 87.0 (67.87 to 95.46) | 87.5 (52.91 to 97.76) | 66.7 (20.77 to 93.85) | 88.9 (56.50 to 98.01) | 91.7 (64.61 to 98.51) | 83.3 (43.65 to 96.99) |
| Week 48 | 94.1 (73.02 to 98.95) | 83.3 (43.65 to 96.99) | 66.7 (20.77 to 93.85) | 85.7 (48.69 to 97.43) | 87.5 (52.91 to 97.76) | 100 (60.97 to 100.00) |
| Week 60 | 88.9 (56.50 to 98.01) | 100 (34.24 to 100.00) | 100 (34.24 to 100.00) | 75.0 (30.06 to 95.44) | 100 (56.55 to 100.00) | 100 (51.01 to 100.00) |
Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 50% response (ACR50) criteria: 1. ≥ 50% improvement in 68-tender joint count from Baseline of Study M16-063 2. ≥ 50% improvement in 66-swollen joint count from Baseline of Study M16-063 and 3. ≥ 50% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063: * Patient's Assessment of Pain (Visual Analog Scale \[VAS\]) * Patient's Global Assessment of Disease Activity (PtGA) * Physician's Global Assessment of Disease Activity (PhGA) * Health Assessment Questionnaire Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP)
| percentage of participants | ABBV-599 in M16-063/ABBV-599 in M16-763 | ABBV-105 60 mg/UPA Placebo | ABBV-105 20 mg/UPA Placebo | ABBV-105 5 mg/UPA Placebo | UPA 15 mg/ABBV-105 Placebo | Placebo in M16-063/ABBV-599 in M16-763 |
|---|---|---|---|---|---|---|
| Week 18 | 68.2 (47.32 to 83.64) | 46.7 (24.81 to 69.88) | 40.0 (16.82 to 68.73) | 40.0 (16.82 to 68.73) | 70.6 (46.87 to 86.72) | 62.5 (30.57 to 86.32) |
| Week 24 | 76.9 (57.95 to 88.97) | 64.3 (38.76 to 83.66) | 42.9 (15.82 to 74.95) | 66.7 (35.42 to 87.94) | 87.5 (63.98 to 96.50) | 100 (67.56 to 100.00) |
| Week 30 | 63.6 (42.95 to 80.27) | 61.5 (35.52 to 82.29) | 16.7 (3.01 to 56.35) | 60.0 (31.27 to 83.18) | 87.5 (63.98 to 96.50) | 100 (67.56 to 100.00) |
| Week 36 | 82.6 (62.86 to 93.02) | 62.5 (30.57 to 86.32) | 33.3 (6.15 to 79.23) | 66.7 (35.42 to 87.94) | 75.0 (46.77 to 91.11) | 66.7 (30.00 to 90.32) |
| Week 48 | 82.4 (58.97 to 93.81) | 66.7 (30.00 to 90.32) | 66.7 (20.77 to 93.85) | 71.4 (35.89 to 91.78) | 87.5 (52.91 to 97.76) | 83.3 (43.65 to 96.99) |
| Week 60 | 88.9 (56.50 to 98.01) | 50.0 (9.45 to 90.55) | 100 (34.24 to 100.00) | 75.0 (30.06 to 95.44) | 100 (56.55 to 100.00) | 100 (51.01 to 100.00) |
Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 70% response (ACR70) criteria: 1. ≥ 70% improvement in 68-tender joint count from Baseline of Study M16-063 2. ≥ 70% improvement in 66-swollen joint count from Baseline of Study M16-063 and 3. ≥ 70% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063: * Patient's Assessment of Pain (Visual Analog Scale \[VAS\]) * Patient's Global Assessment of Disease Activity (PtGA) * Physician's Global Assessment of Disease Activity (PhGA) * Health Assessment Questionnaire Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP)
| percentage of participants | ABBV-599 in M16-063/ABBV-599 in M16-763 | ABBV-105 60 mg/UPA Placebo | ABBV-105 20 mg/UPA Placebo | ABBV-105 5 mg/UPA Placebo | UPA 15 mg/ABBV-105 Placebo | Placebo in M16-063/ABBV-599 in M16-763 |
|---|---|---|---|---|---|---|
| Week 18 | 47.8 (29.24 to 67.04) | 33.3 (15.18 to 58.29) | 20.0 (5.67 to 50.98) | 25.0 (8.89 to 53.23) | 55.6 (33.72 to 75.44) | 37.5 (13.68 to 69.43) |
| Week 24 | 57.7 (38.95 to 74.46) | 42.9 (21.38 to 67.41) | 12.5 (2.24 to 47.09) | 55.6 (26.67 to 81.12) | 62.5 (38.64 to 81.52) | 87.5 (52.91 to 97.76) |
| Week 30 | 63.6 (42.95 to 80.27) | 46.2 (23.21 to 70.86) | 14.3 (2.57 to 51.31) | 60.0 (31.27 to 83.18) | 68.8 (44.40 to 85.84) | 87.5 (52.91 to 97.76) |
| Week 36 | 78.3 (58.10 to 90.34) | 50.0 (21.52 to 78.48) | 25.0 (4.56 to 69.94) | 44.4 (18.88 to 73.33) | 75.0 (46.77 to 91.11) | 66.7 (30.00 to 90.32) |
| Week 48 | 58.8 (36.01 to 78.39) | 50.0 (18.76 to 81.24) | 25.0 (4.56 to 69.94) | 42.9 (15.82 to 74.95) | 75.0 (40.93 to 92.85) | 83.3 (43.65 to 96.99) |
| Week 60 | 88.9 (56.50 to 98.01) | 50.0 (9.45 to 90.55) | 50.0 (9.45 to 90.55) | 25.0 (4.56 to 69.94) | 60.0 (23.07 to 88.24) | 75.0 (30.06 to 95.44) |
Sixty-six joints were assessed for swelling by physical examination. Swelling of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with swelling) to 66 (worst possible score/66 joints with swelling). Negative values indicate improvement from baseline.
| swollen joint counts | ABBV-599 in M16-063/ABBV-599 in M16-763 | ABBV-105 60 mg/UPA Placebo | ABBV-105 20 mg/UPA Placebo | ABBV-105 5 mg/UPA Placebo | UPA 15 mg/ABBV-105 Placebo | Placebo in M16-063/ABBV-599 in M16-763 |
|---|---|---|---|---|---|---|
| Week 18 | -11.50 (-13.66 to -9.34) | -9.88 (-14.37 to -5.38) | -8.00 (-11.28 to -4.72) | -13.42 (-18.40 to -8.43) | -12.80 (-16.11 to -9.49) | -9.78 (-13.06 to -6.50) |
| Week 24 | -11.67 (-13.85 to -9.49) | -10.54 (-14.25 to -6.82) | -7.67 (-10.13 to -5.21) | -15.60 (-21.14 to -10.06) | -13.24 (-16.48 to -9.99) | -10.38 (-14.22 to -6.53) |
| Week 30 | -11.87 (-14.53 to -9.21) | -7.69 (-11.64 to -3.74) | -5.86 (-8.27 to -3.44) | -15.50 (-21.05 to -9.95) | -13.44 (-17.11 to -9.77) | -10.75 (-14.61 to -6.89) |
| Week 36 | -12.38 (-14.84 to -9.91) | -10.13 (-13.42 to -6.83) | -7.75 (-11.73 to -3.77) | -14.60 (-21.38 to -7.82) | -14.25 (-18.71 to -9.79) | -10.50 (-14.79 to -6.21) |
| Week 48 | -13.67 (-16.57 to -10.77) | -8.00 (-16.13 to 0.13) | -8.00 (-11.90 to -4.10) | -15.88 (-21.34 to -10.41) | -15.75 (-21.84 to -9.66) | -10.67 (-15.34 to -5.99) |
| Week 60 | -14.44 (-17.73 to -11.16) | -12.50 (-18.85 to -6.15) | -7.50 (-39.27 to 24.27) | -15.40 (-23.66 to -7.14) | -13.00 (-20.80 to -5.20) | -11.25 (-16.00 to -6.50) |
Sixty-eight joints were assessed for tenderness by physical examination. Pain or tenderness of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with tenderness) to 68 (worst possible score/68 joints with tenderness). Negative values indicate improvement from baseline.
| tender joint counts | ABBV-599 in M16-063/ABBV-599 in M16-763 | ABBV-105 60 mg/UPA Placebo | ABBV-105 20 mg/UPA Placebo | ABBV-105 5 mg/UPA Placebo | UPA 15 mg/ABBV-105 Placebo | Placebo in M16-063/ABBV-599 in M16-763 |
|---|---|---|---|---|---|---|
| Week 18 | -17.29 (-20.95 to -13.62) | -12.69 (-18.77 to -6.61) | -9.82 (-13.63 to -6.01) | -14.17 (-21.70 to -6.63) | -19.75 (-25.63 to -13.87) | -10.67 (-16.21 to -5.12) |
| Week 24 | -17.93 (-21.84 to -14.02) | -15.77 (-19.37 to -12.17) | -8.11 (-10.95 to -5.28) | -20.20 (-26.97 to -13.43) | -20.76 (-27.39 to -14.14) | -14.25 (-18.44 to -10.06) |
| Week 30 | -16.30 (-20.32 to -12.29) | -9.54 (-18.16 to -0.92) | -4.57 (-7.29 to -1.86) | -19.80 (-27.25 to -12.35) | -20.50 (-28.45 to -12.55) | -14.88 (-18.60 to -11.15) |
| Week 36 | -16.42 (-20.15 to -12.68) | -15.25 (-19.85 to -10.65) | -8.00 (-15.46 to -0.54) | -18.40 (-26.99 to -9.81) | -24.92 (-33.96 to -15.88) | -14.83 (-19.21 to -10.46) |
| Week 48 | -17.33 (-21.05 to -13.61) | -12.33 (-23.09 to -1.58) | -5.50 (-14.64 to 3.64) | -18.88 (-28.63 to -9.12) | -28.88 (-41.80 to -15.95) | -15.00 (-20.10 to -9.90) |
| Week 60 | -19.78 (-25.14 to -14.41) | -19.00 (-82.53 to 44.53) | -11.50 (-81.38 to 58.38) | -20.20 (-35.42 to -4.98) | -26.20 (-36.90 to -15.50) | -15.50 (-21.52 to -9.48) |
Participants rated their pain on a visual analogue scale (VAS) of 0 to 100 (mm), with 0 representing no pain and 100 representing the worst possible pain. Negative values indicate improvement from baseline.
| units on a scale | ABBV-599 in M16-063/ABBV-599 in M16-763 | ABBV-105 60 mg/UPA Placebo | ABBV-105 20 mg/UPA Placebo | ABBV-105 5 mg/UPA Placebo | UPA 15 mg/ABBV-105 Placebo | Placebo in M16-063/ABBV-599 in M16-763 |
|---|---|---|---|---|---|---|
| Week 18 | -49.68 (-62.42 to -36.94) | -34.67 (-51.73 to -17.61) | -25.57 (-56.51 to 5.37) | -32.50 (-53.25 to -11.75) | -56.17 (-72.40 to -39.93) | -47.88 (-76.92 to -18.83) |
| Week 24 | -45.46 (-58.31 to -32.61) | -48.36 (-60.60 to -36.11) | -29.43 (-50.47 to -8.39) | -42.00 (-61.74 to -22.26) | -57.76 (-73.67 to -41.86) | -59.38 (-80.35 to -38.40) |
| Week 30 | -48.18 (-61.90 to -34.46) | -40.62 (-63.40 to -17.83) | -20.00 (-48.48 to 8.48) | -45.90 (-70.64 to -21.16) | -53.63 (-71.19 to -36.06) | -60.25 (-80.74 to -39.76) |
| Week 36 | -49.22 (-61.84 to -36.59) | -47.13 (-72.05 to -22.20) | -25.67 (-120.27 to 68.94) | -46.70 (-63.40 to -30.00) | -58.83 (-80.69 to -36.98) | -54.83 (-90.68 to -18.98) |
| Week 48 | -60.06 (-72.78 to -47.34) | -49.00 (-72.85 to -25.15) | -35.00 (-69.15 to -0.85) | -56.13 (-82.80 to -29.45) | -58.75 (-82.80 to -34.70) | -61.50 (-94.46 to -28.54) |
| Week 60 | -54.67 (-77.99 to -31.34) | -52.00 (-522.13 to 418.13) | -45.50 (-140.80 to 49.80) | -58.80 (-73.74 to -43.86) | -61.00 (-88.13 to -33.87) | -55.00 (-100.36 to -9.64) |
Participants rated their disease activity for the past 24 hours using a Patient's Global Assessment of Disease Activity Global visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.
| units on a scale | ABBV-599 in M16-063/ABBV-599 in M16-763 | ABBV-105 60 mg/UPA Placebo | ABBV-105 20 mg/UPA Placebo | ABBV-105 5 mg/UPA Placebo | UPA 15 mg/ABBV-105 Placebo | Placebo in M16-063/ABBV-599 in M16-763 |
|---|---|---|---|---|---|---|
| Week 18 | -45.18 (-58.36 to -32.00) | -34.07 (-50.11 to -18.03) | -28.57 (-61.69 to 4.55) | -35.70 (-56.96 to -14.44) | -56.56 (-72.18 to -40.93) | -40.13 (-67.21 to -13.04) |
| Week 24 | -48.62 (-59.37 to -37.87) | -45.93 (-60.14 to -31.72) | -33.29 (-59.62 to -6.95) | -45.20 (-61.30 to -29.10) | -62.47 (-76.09 to -48.85) | -58.13 (-74.96 to -41.29) |
| Week 30 | -46.18 (-60.77 to -31.60) | -39.69 (-61.63 to -17.76) | -21.40 (-57.54 to 14.74) | -45.20 (-67.27 to -23.13) | -56.31 (-71.70 to -40.92) | -57.75 (-75.80 to -39.70) |
| Week 36 | -51.70 (-64.00 to -39.39) | -48.63 (-73.95 to -23.30) | -31.67 (-141.65 to 78.32) | -46.20 (-64.52 to -27.88) | -61.00 (-81.17 to -40.83) | -53.33 (-84.24 to -22.42) |
| Week 48 | -54.24 (-69.66 to -38.81) | -44.00 (-71.07 to -16.93) | -38.67 (-88.62 to 11.28) | -53.13 (-76.82 to -29.43) | -60.75 (-84.13 to -37.37) | -56.67 (-84.14 to -29.19) |
| Week 60 | -56.67 (-83.18 to -30.16) | -56.00 (-462.60 to 350.60) | -54.50 (-226.03 to 117.03) | -54.60 (-70.61 to -38.59) | -59.80 (-96.50 to -23.10) | -57.00 (-87.75 to -26.25) |
The physician assessed a participant's disease activity at the time of the visit using a Physician's Global Assessment of Disease visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.
| units on a scale | ABBV-599 in M16-063/ABBV-599 in M16-763 | ABBV-105 60 mg/UPA Placebo | ABBV-105 20 mg/UPA Placebo | ABBV-105 5 mg/UPA Placebo | UPA 15 mg/ABBV-105 Placebo | Placebo in M16-063/ABBV-599 in M16-763 |
|---|---|---|---|---|---|---|
| Week 18 | -57.22 (-65.56 to -48.87) | -41.00 (-53.42 to -28.58) | -33.00 (-61.23 to -4.77) | -35.00 (-59.98 to -10.02) | -59.06 (-69.39 to -48.72) | -55.13 (-82.03 to -28.22) |
| Week 24 | -57.93 (-65.61 to -50.25) | -48.36 (-60.05 to -36.66) | -39.43 (-70.88 to -7.98) | -50.89 (-68.36 to -33.42) | -61.19 (-71.90 to -50.47) | -62.38 (-77.73 to -47.02) |
| Week 30 | -55.04 (-64.27 to -45.82) | -41.23 (-57.85 to -24.61) | -41.80 (-60.33 to -23.27) | -54.78 (-71.11 to -38.45) | -56.20 (-73.22 to -39.18) | -63.50 (-79.15 to -47.85) |
| Week 36 | -57.55 (-66.96 to -48.13) | -53.75 (-70.49 to -37.01) | -60.00 (-112.58 to -7.42) | -54.78 (-73.97 to -35.58) | -68.45 (-81.66 to -55.25) | -65.83 (-89.60 to -42.06) |
| Week 48 | -56.39 (-71.53 to -41.24) | -36.83 (-75.18 to 1.52) | -56.67 (-93.29 to -20.04) | -57.14 (-80.22 to -34.07) | -66.13 (-82.33 to -49.92) | -66.40 (-89.67 to -43.13) |
| Week 60 | -64.33 (-79.18 to -49.48) | -56.00 (-437.19 to 325.19) | -65.00 (-141.24 to 11.24) | -61.50 (-88.83 to -34.17) | -60.00 (-88.34 to -31.66) | -56.75 (-87.94 to -25.56) |
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from baseline in the overall score indicates improvement.
| units on a scale | ABBV-599 in M16-063/ABBV-599 in M16-763 | ABBV-105 60 mg/UPA Placebo | ABBV-105 20 mg/UPA Placebo | ABBV-105 5 mg/UPA Placebo | UPA 15 mg/ABBV-105 Placebo | Placebo in M16-063/ABBV-599 in M16-763 |
|---|---|---|---|---|---|---|
| Week 18 | -0.57 (-0.84 to -0.29) | -0.49 (-0.84 to -0.14) | -0.61 (-1.27 to 0.06) | -0.61 (-1.04 to -0.19) | -0.85 (-1.21 to -0.50) | -0.47 (-0.77 to -0.17) |
| Week 24 | -0.59 (-0.81 to -0.36) | -0.46 (-0.80 to -0.12) | -0.57 (-1.24 to 0.09) | -0.54 (-0.98 to -0.09) | -0.59 (-0.94 to -0.25) | -0.78 (-1.29 to -0.27) |
| Week 30 | -0.64 (-0.91 to -0.36) | -0.45 (-0.93 to 0.03) | -0.15 (-0.45 to 0.15) | -0.51 (-0.94 to -0.09) | -0.73 (-1.10 to -0.35) | -0.75 (-1.17 to -0.33) |
| Week 36 | -0.67 (-0.95 to -0.38) | -0.70 (-1.45 to 0.05) | -0.33 (-0.81 to 0.14) | -0.30 (-0.70 to 0.10) | -0.51 (-0.94 to -0.09) | -0.56 (-1.05 to -0.07) |
| Week 48 | -0.70 (-1.06 to -0.34) | -0.63 (-1.76 to 0.51) | -0.29 (-0.65 to 0.07) | -0.42 (-0.90 to 0.06) | -0.39 (-0.83 to 0.05) | -0.71 (-1.17 to -0.25) |
| Week 60 | -0.78 (-1.22 to -0.34) | -0.75 (-13.46 to 11.96) | -0.31 (-4.28 to 3.66) | -0.58 (-1.30 to 0.15) | -0.48 (-1.77 to 0.82) | -0.72 (-1.61 to 0.18) |
C-reactive protein is a blood test marker for inflammation in the body, and levels rise in response to inflammation. A negative change from baseline indicates improvement.
| mg/L | ABBV-599 in M16-063/ABBV-599 in M16-763 | ABBV-105 60 mg/UPA Placebo | ABBV-105 20 mg/UPA Placebo | ABBV-105 5 mg/UPA Placebo | UPA 15 mg/ABBV-105 Placebo | Placebo in M16-063/ABBV-599 in M16-763 |
|---|---|---|---|---|---|---|
| Week 18 | -16.04 (-24.13 to -7.95) | 5.34 (-9.84 to 20.53) | -0.96 (-6.20 to 4.28) | -14.85 (-34.27 to 4.57) | -11.48 (-16.88 to -6.07) | -10.00 (-28.36 to 8.35) |
| Week 24 | -15.08 (-23.26 to -6.90) | -0.20 (-15.16 to 14.76) | -2.18 (-4.30 to -0.06) | -15.09 (-38.53 to 8.34) | -9.48 (-15.35 to -3.60) | -13.16 (-32.31 to 5.99) |
| Week 30 | -16.61 (-27.35 to -5.88) | -6.00 (-24.37 to 12.36) | -1.66 (-4.91 to 1.59) | -17.11 (-44.18 to 9.95) | -9.55 (-14.24 to -4.85) | -16.22 (-28.83 to -3.61) |
| Week 36 | -13.88 (-23.43 to -4.32) | -12.43 (-27.58 to 2.73) | -1.58 (-11.33 to 8.18) | -13.61 (-34.50 to 7.28) | -7.76 (-13.95 to -1.56) | -18.34 (-37.30 to 0.62) |
| Week 48 | -16.41 (-28.14 to -4.69) | -18.38 (-50.37 to 13.60) | -5.99 (-17.43 to 5.45) | -20.18 (-49.36 to 9.00) | -7.22 (-14.57 to 0.14) | -18.30 (-36.16 to -0.44) |
| Week 60 | -25.69 (-45.41 to -5.98) | -31.46 (-288.63 to 225.71) | -3.98 (-116.05 to 108.09) | -25.58 (-67.98 to 16.83) | -3.34 (-23.18 to 16.50) | -12.47 (-33.61 to 8.67) |
Morning stiffness severity was assessed by a numeric rating-scale (NRS). Participants rated the severity of morning stiffness during the past week from 0 to 10 with 0 representing "not severe" and 10 "very severe". Negative values indicate improvement from baseline.
| units on a scale | ABBV-599 in M16-063/ABBV-599 in M16-763 | ABBV-105 60 mg/UPA Placebo | ABBV-105 20 mg/UPA Placebo | ABBV-105 5 mg/UPA Placebo | UPA 15 mg/ABBV-105 Placebo | Placebo in M16-063/ABBV-599 in M16-763 |
|---|---|---|---|---|---|---|
| Week 18 | -4.27 (-5.56 to -2.99) | -2.27 (-3.69 to -0.84) | -2.14 (-4.99 to 0.70) | -3.40 (-6.02 to -0.78) | -5.29 (-6.54 to -4.05) | -2.38 (-4.65 to -0.10) |
| Week 24 | -4.48 (-5.52 to -3.44) | -2.64 (-3.81 to -1.47) | -3.29 (-5.89 to -0.69) | -3.70 (-5.21 to -2.19) | -4.88 (-6.43 to -3.32) | -3.50 (-5.50 to -1.50) |
| Week 30 | -4.36 (-5.83 to -2.90) | -2.23 (-4.28 to -0.18) | -1.20 (-2.82 to 0.42) | -4.20 (-5.66 to -2.74) | -4.53 (-5.75 to -3.32) | -3.13 (-5.55 to -0.70) |
| Week 36 | -4.43 (-5.95 to -2.92) | -3.38 (-5.74 to -1.01) | -1.00 (-5.30 to 3.30) | -4.00 (-5.39 to -2.61) | -5.55 (-6.80 to -4.29) | -3.00 (-6.18 to 0.18) |
| Week 48 | -5.47 (-6.64 to -4.30) | -3.33 (-6.49 to -0.17) | -1.00 (-7.57 to 5.57) | -4.13 (-6.67 to -1.58) | -5.38 (-7.10 to -3.65) | -3.67 (-6.90 to -0.44) |
| Week 60 | -4.89 (-6.54 to -3.24) | -4.50 (-23.56 to 14.56) | -3.00 (NA to NA) | -4.40 (-6.66 to -2.14) | -4.80 (-7.19 to -2.41) | -3.00 (-5.25 to -0.75) |
Collected over All-cause mortality is reported from enrollment to the end of study; median time on follow-up was ABBV-599 in M16-063/M16-763 (279 days); ABBV-105 60 mg/UPA placebo (183 days); ABBV-105 20 mg/UPA placebo (159 days); ABBV-105 5 mg/UPA placebo (337 days); UPA 15 mg/ABBV-105 placebo (229 days); and Placebo in M16-063/ABBV-599 in M16-763 (281 days). TEAEs/SAEs were collected from the first dose in M16-763 until 30 days after last dose, up to 52 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABBV-599 in M16-063/ABBV-599 in M16-763 | 0/28 (0%) | 1/28 (3.6%) | 8/28 (28.6%) |
| ABBV-105 60 mg/UPA Placebo | 0/16 (0%) | 0/16 (0%) | 10/16 (62.5%) |
| ABBV-105 20 mg/UPA Placebo | 0/12 (0%) | 0/12 (0%) | 3/12 (25%) |
| ABBV-105 5 mg/UPA Placebo | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| UPA 15 mg/ABBV-105 Placebo | 0/20 (0%) | 1/20 (5%) | 7/20 (35%) |
| Placebo in M16-063/ABBV-599 in M16-763 | 0/9 (0%) | 0/9 (0%) | 3/9 (33.3%) |
| Event | ABBV-599 in M16-063/ABBV-599 in M16-763 | ABBV-105 60 mg/UPA Placebo | ABBV-105 20 mg/UPA Placebo | ABBV-105 5 mg/UPA Placebo | UPA 15 mg/ABBV-105 Placebo | Placebo in M16-063/ABBV-599 in M16-763 |
|---|---|---|---|---|---|---|
| PERIPROSTHETIC FRACTUREInjury, poisoning and procedural complications | 0/28 | 0/16 | 0/12 | 0/12 | 1/20 | 0/9 |
| LUNG ADENOCARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/28 | 0/16 | 0/12 | 0/12 | 0/20 | 0/9 |
| Event | ABBV-599 in M16-063/ABBV-599 in M16-763 | ABBV-105 60 mg/UPA Placebo | ABBV-105 20 mg/UPA Placebo | ABBV-105 5 mg/UPA Placebo | UPA 15 mg/ABBV-105 Placebo | Placebo in M16-063/ABBV-599 in M16-763 |
|---|---|---|---|---|---|---|
| RHEUMATOID ARTHRITISMusculoskeletal and connective tissue disorders | 2/28 | 4/16 | 0/12 | 0/12 | 0/20 | 0/9 |
| DRUG WITHDRAWAL SYNDROMEGeneral disorders | 0/28 | 0/16 | 0/12 | 0/12 | 0/20 | 1/9 |
| INFLUENZA LIKE ILLNESSGeneral disorders | 0/28 | 0/16 | 0/12 | 0/12 | 0/20 | 1/9 |
| URINARY TRACT INFECTIONInfections and infestations | 1/28 | 0/16 | 0/12 | 0/12 | 2/20 | 1/9 |
| HYPERGLYCAEMIAMetabolism and nutrition disorders | 0/28 | 0/16 | 0/12 | 0/12 | 0/20 | 1/9 |
| BASAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/28 | 0/16 | 0/12 | 0/12 | 0/20 | 1/9 |
| DIZZINESSNervous system disorders | 0/28 | 0/16 | 0/12 | 0/12 | 0/20 | 1/9 |
| DEPRESSIONPsychiatric disorders | 0/28 | 0/16 | 0/12 | 0/12 | 0/20 | 1/9 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 3/28 | 1/16 | 0/12 | 1/12 | 1/20 | 0/9 |
| ANAEMIABlood and lymphatic system disorders | 0/28 | 0/16 | 0/12 | 1/12 | 0/20 | 0/9 |
Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763
| Age, Continuous(years) | ABBV-599 in M16-063/ABBV-599 in M16-763 | ABBV-105 60 mg/UPA Placebo | ABBV-105 20 mg/UPA Placebo | ABBV-105 5 mg/UPA Placebo | UPA 15 mg/ABBV-105 Placebo | Placebo in M16-063/ABBV-599 in M16-763 | Total |
|---|---|---|---|---|---|---|---|
| Mean | 57.5 ± 12.64 | 58.6 ± 8.75 | 58.5 ± 12.07 | 54.5 ± 12.21 | 61.7 ± 8.99 | 59.4 ± 9.48 | 58.5 ± 10.89 |
| Sex: Female, Male(Participants) | ABBV-599 in M16-063/ABBV-599 in M16-763 | ABBV-105 60 mg/UPA Placebo | ABBV-105 20 mg/UPA Placebo | ABBV-105 5 mg/UPA Placebo | UPA 15 mg/ABBV-105 Placebo | Placebo in M16-063/ABBV-599 in M16-763 | Total |
|---|---|---|---|---|---|---|---|
| Female | 18 | 14 | 12 | 8 | 18 | 7 | 77 |
| Male | 10 | 2 | 0 | 4 | 2 | 2 | 20 |
| Race/Ethnicity, Customized(Participants) | ABBV-599 in M16-063/ABBV-599 in M16-763 | ABBV-105 60 mg/UPA Placebo | ABBV-105 20 mg/UPA Placebo | ABBV-105 5 mg/UPA Placebo | UPA 15 mg/ABBV-105 Placebo | Placebo in M16-063/ABBV-599 in M16-763 | Total |
|---|---|---|---|---|---|---|---|
| White | 27 | 15 | 12 | 12 | 20 | 9 | 95 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Duration of Rheumatoid Arthritis Diagnosis(years) | ABBV-599 in M16-063/ABBV-599 in M16-763 | ABBV-105 60 mg/UPA Placebo | ABBV-105 20 mg/UPA Placebo | ABBV-105 5 mg/UPA Placebo | UPA 15 mg/ABBV-105 Placebo | Placebo in M16-063/ABBV-599 in M16-763 | Total |
|---|---|---|---|---|---|---|---|
| Mean | 10.024 ± 5.6087 | 14.212 ± 9.0327 | 5.435 ± 3.2458 | 9.466 ± 6.6508 | 13.571 ± 7.8086 | 9.684 ± 5.6087 | 10.778 ± 7.0861 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvie.com
Ran from May 2019 to primary completion in Sep 2020, 15 months.
Results were first posted in Sep 2021, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elsubrutinib · Upadacitinib